Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and the best dose of vorinostat when given
together with isotretinoin to see how well it works in treating patients with high-risk
refractory or recurrent neuroblastoma. Vorinostat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Isotretinoin may help vorinostat work
better by making tumor cells more sensitive to the drug. Giving vorinostat together with
isotretinoin may be an effective treatment for neuroblastoma.